Patents by Inventor Paul E. Finke

Paul E. Finke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Assay for evaluating inhibition of polymorphonuclear leukocyte elastase by N-substituted azetidinones
    Patent number: 5420010
    Abstract: N-substituted azetidinones are a class of inhibitors of human leukocytes elastase which are known to be useful in the treatment of a wide variety of antiinflammatory and antidegenerative diseases. In inhibiting elastase, the therapeutic agents are shown to form a characteristic stable complex with the enzyme. In the assay disclosed herein, the inhibitor-enzyme complex is advantageously hydrolyzed and specific product(s) of the hydrolysis are measured. The assays are useful in a clinical setting, for determining appropriate dosage and assessing the effectiveness of treatment.
    Type: Grant
    Filed: July 30, 1993
    Date of Patent: May 30, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Paul E. Finke, William K. Hagmann, William A. Hanlon, John L. Humes, Wilson B. Knight, Malcolm MacCoss, Richard A. Mumford, Shrenik K. Shah
  • Process of making chiral 2-aryl-1,4-butanediamine derivatives as useful neurokinin-A antagonists
    Patent number: 5391819
    Abstract: Disclosed herein is a process of making chiral 2-aryl-1,4-butanediamine derivatives useful as neurokinin-A antagonists of Formula 7 ##STR1##
    Type: Grant
    Filed: September 30, 1992
    Date of Patent: February 21, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Paul E. Finke, Jeffrey J. Hale, Malcolm Maccoss, Sander G. Mills
  • Alicyclic compounds as tachykinin receptor antagonists
    Patent number: 5387595
    Abstract: Substituted alicyclic compounds of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, and asthma.
    Type: Grant
    Filed: August 26, 1992
    Date of Patent: February 7, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Sander G. Mills, Paul E. Finke, Malcolm MacCoss, Daniel J. Miller, Dennis J. Underwood
  • Substituted cephalosporin sulfones as anti-inflammatory and antidegenerative agents
    Patent number: 5364848
    Abstract: New substituted cephalosporin sulfones are found to be potent elastase inhibitors and thereby useful anti-inflammatory/antidegenerative agents.
    Type: Grant
    Filed: May 1, 1992
    Date of Patent: November 15, 1994
    Assignee: Merck & Co., Inc.
    Inventors: James B. Doherty, Raymond A. Firestone, Paul E. Finke, William K. Hagmann, Shrenik K. Shah, Kevan R. Thompson
  • Substituted azetidinones as anti-inflammatory and antidegenerative agents
    Patent number: 5348953
    Abstract: New substituted azetidinones of the general formula (I) which have been found to be potent elastase inhibitors and thereby useful anti-inflammatory and antidegenerative agents are described.
    Type: Grant
    Filed: December 17, 1992
    Date of Patent: September 20, 1994
    Assignee: Merck & Co., Inc.
    Inventors: James B. Doherty, Paul E. Finke, William K. Hagmann, Amy L. Kissinger, Malcolm MacCoss, Shrenik K. Shah
  • Haptens useful in evaluating inhibition of PNN elastase by N-substituted azetidinones
    Patent number: 5276139
    Abstract: N-substituted azetidinones are a class of inhibitors of human leukocytes elastase which are known to be useful in the treatment of a wide variety of antiinflammatory and antidegenerative diseases. In inhibiting elastase, the therapeutic agents are shown to form a characteristic stable complex with the enzyme. In the radioimmune assay disclosed herein, the inhibitor-enzyme complex is advantageously hydrolyzed and specific product(s) of the hydrolysis are measured. The assays are useful in a clinical setting, for determining appropriate dosage and assessing the effectiveness of treatment.
    Type: Grant
    Filed: August 26, 1991
    Date of Patent: January 4, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Paul E. Finke, William K. Hagmann, Richard A. Mumford, Shrenik K. Shah
  • Substituted azetidinones as anti-inflammatory and antidegenerative agents
    Patent number: 5229381
    Abstract: New substituted azetidinones of the general formula (A') which have been found to be potent elastase inhibitors and thereby useful anti-inflammatory and antidegenerative agents are described.
    Type: Grant
    Filed: September 20, 1991
    Date of Patent: July 20, 1993
    Assignee: Merck & Co., Inc.
    Inventors: James B. Doherty, Conrad P. Dorn, Paul E. Finke, William K. Hagmann, Malcolm MacCoss, Shrenik K. Shah
  • Substituted cephalosporin sulfones as anti-inflammatory and anti-degenerative agents
    Patent number: 5132301
    Abstract: New substituted cephalosporin sulfones are found to be potent elastase inhibitors and thereby useful anti-inflammatory/antidegenerative agents.
    Type: Grant
    Filed: January 29, 1990
    Date of Patent: July 21, 1992
    Assignee: Merck & Co., Inc.
    Inventors: James B. Doherty, Raymond A. Firestone, Paul E. Finke, William K. Hagmann, Shrenik K. Shah, Kevan R. Thompson
  • Penicillin derivatives as anti-inflammatory and antidegenerative agents
    Patent number: 4847247
    Abstract: Derivatives of Penicillin, their sulfoxides and sulfones are found to be potent elastase inhibitors and thereby useful anti-inflammatory/antidegenerative agents.
    Type: Grant
    Filed: October 16, 1986
    Date of Patent: July 11, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Kevan R. Thompson, Paul E. Finke, James B. Doherty
  • Tetrazolyl derivatives of beta-lactams useful as elastase inhibitors
    Patent number: 4845088
    Abstract: Tetrazolyl derivatives of .beta.-lactams are found to be potent elastase inhibitors and thereby useful anti-inflammatory/antidegenerative agents.
    Type: Grant
    Filed: June 5, 1987
    Date of Patent: July 4, 1989
    Assignee: Merck & Co., Inc.
    Inventors: James B. Doherty, William K. Hagmann, Paul E. Finke, Shrenik K. Shah
  • .beta.-Lactam derivatives as anti-inflammatory and antidegenerative agents
    Patent number: 4797396
    Abstract: .beta.-Lactam derivatives and analogs are found to be potent elastase inhibitors and thereby useful anti-inflammatory/antidegenerative agents.
    Type: Grant
    Filed: July 16, 1987
    Date of Patent: January 10, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Paul E. Finke, Morris Zimmerman, James B. Doherty, Bonnie M. Ashe, Conrad P. Dorn
  • .beta.-lactam derivatives as anti-inflammatory and antidegenerative agents
    Patent number: 4711886
    Abstract: .beta.-Lactam derivatives and analogs are found to be potent elastase inhibitors and thereby useful anti-inflammatory/antidegenerative agents.
    Type: Grant
    Filed: July 2, 1984
    Date of Patent: December 8, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Paul E. Finke, James B. Doherty, Morris Zimmerman, Bonnie M. Ashe, Conrad P. Dorn
  • Tetrazolyl derivatives of .beta.-lactams useful as elastase inhibitors
    Patent number: 4699904
    Abstract: Tetrazolyl derivatives of .beta.-lactams are found to be potent elastase inhibitors and thereby useful anti-inflammatory/antidegenerative agents.
    Type: Grant
    Filed: July 1, 1985
    Date of Patent: October 13, 1987
    Assignee: Merck & Co., Inc.
    Inventors: James B. Doherty, Paul E. Finke, William K. Hagmann, Shrenik K. Shah
  • Substituted cephalosporins as anti-inflammatory and antidegenerative agents
    Patent number: 4637999
    Abstract: Substituted cephalosporins are found to be potent elastase inhibitors and thereby useful antiinflammatory/antidegenerative agents.
    Type: Grant
    Filed: May 2, 1983
    Date of Patent: January 20, 1987
    Assignee: Merck & Co., Inc.
    Inventors: James B. Doherty, Paul E. Finke, Raymond A. Firestone, Shrenik S. Shah, Kevan R. Thompson
  • Substituted cephalosporin sulfoxides as anti-inflammatory and antidegenerative agents
    Patent number: 4623645
    Abstract: Substituted cephalosporin sulfoxides are found to be potent elastase inhibitors and thereby useful anti-inflammatory/antidegenerative agents.
    Type: Grant
    Filed: April 18, 1983
    Date of Patent: November 18, 1986
    Assignee: Merck & Co., Inc.
    Inventors: James B. Doherty, Bonnie M. Ashe, Paul E. Finke, Raymond A. Firestone, Shrenik K. Shah, Morris Zimmerman
  • Substituted cephalosporin sulfones as anti-inflammatory and anti-degenerative agents
    Patent number: 4547371
    Abstract: Substituted cephalosporin sulfones are found to be potent elastase inhibitors and thereby useful anti-inflammatory/antidegenerative agents.
    Type: Grant
    Filed: April 18, 1983
    Date of Patent: October 15, 1985
    Assignee: Merck & Co., Inc.
    Inventors: James B. Doherty, Bonnie M. Ashe, Paul E. Finke, Shrenik K. Shah, Kevan R. Thompson, Morris Zimmerman
  • Process for preparing Benzoxepino- or Benzthiapino[4,3-b]pyrrole-2-acetic acids
    Patent number: 4380645
    Abstract: Improved yields of Benzoxepino- or Benzthiapino[4,3-b]pyrrole-2-acetic acids have been achieved from processes based on modifications performed on a pyrrole carboxylic ester rather than on a pyrrole-.alpha.-oxoacetate.
    Type: Grant
    Filed: December 11, 1981
    Date of Patent: April 19, 1983
    Assignee: Merck & Co., Inc.
    Inventors: Bruce E. Witzel, Paul E. Finke, Debra L. Allison